Neuroendocrine Carcinoma, Neuroendocrine Tumors
Conditions
Brief summary
The main objective of this clinical trial represents the evaluation of efficacy of the tyrosine kinase inhibitor Cabozantinib in patients with NEN G3 with a proliferation rate of Ki67 20 - 60%.
Interventions
DRUGCabozantinib
Cabozantinib is administered orally at the dose of 60 mg per day..
Sponsors
Karsten Gavenis
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient with histologically confirmed diagnosis of neuroendocrine neoplasia; 2. Tumor proliferation rate has to be between Ki67 20% to 60% (local assessment); 3. Male, female, or diverse patients aged \> 18 years without upper age limit; 4. At least one measurable tumor lesions in CT or MRI scan; 5. Newly diagnosed or progressive disease assessed per RECIST criteria 1.1; 6. Patients must have a performance status of ECOG 0-2; 7. Patients must have a life expectancy of more than 3 months; 8. Hb\> 9 mg/dl; 9. platelets \>80T/µl; 10. white blood cells \>3T/μL; 11. total bilirubin \<3mg/dl; 12. AST and ALT \<4xN; 13. Serum creatinine \<2mg/dl, eGFR \>40mL/min/1.73m2; 14. BUN \<5xN; 15. lipase \<3xN; 16. albumin ≥2.8 g/dL; 17. PT/PTT ≤ 1.5 × ULN; 18. urine protein: creatinine ratio ≤ 1; 19. Written informed consent obtained according to international guidelines and local laws; 20. Ability to understand the nature of the trial and the trial related procedures and to comply with them;
Exclusion criteria
1. Patients younger than 18 years; 2. Patients with Mixed Neuroendocrine-Non-neuroendocrine Neoplasia (MINEN); 3. Patients with former treatment with TKI or VEGF receptor antagonist; 4. Patients with additional malignancy \<5 years in medical history (exclusion: non-invasive skin cancer); 5. Patients with symptomatic brain metastases; 6. Patients with Known HIV infection, infectious hepatitis (type A, B or C) or another uncontrolled infection; 7. Patients with Known hypersensitivity to Cabozantinib or contraindications for treatment with Cabozantinib according to Summary of Product Characteristics (SmPC); 8. Patients with class III or IV congestive heart failure; 9. Patients with QTc more than 500 ms or 140% of normal range according to age; 10. Patients with uncontrolled hypertension; 11. Patients with severely impaired lung function; 12. Patients with history of organ transplant (exclusion: cornea transplantation); 13. Patients with clinical apparent acute or chronic gastric ulceration; 14. Patients with history of hemophilia; 15. Patients with surgery at the GI tract within the last 12 weeks; 16. Patients with patients with uncontrolled inflammatory bowel disease; 17. Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed 18. Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial; 19. Previous participation in this trial 20. concomitant use of therapeutic anticoagulation or strong CYP3A4 inducers or inhibitors (e.g. amiodarone); 21. Known or persistent abuse of medication, drugs or alcohol; 22. Person who is in a relationship of dependence/employment with the sponsor or the investigator; 23. Patients who cannot give informed consent; 24. Current or planned pregnancy, nursing period;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the efficacy of Cabozantinib treatment via DCR after 6 months. | 6 months | Disease control rate (DCR) 6 months after treatment start . |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate short- and long term efficacy of Cabozantinib treatment via DCR. | 12 months | DCR 3 and 12 months after treatment start. |
| Evaluate short- and long term efficacy of Cabozantinib treatment via ORR. | 12 months | Objective response rate (ORR) 3, 6 and 12 months after treatment start and best objective response rate. |
| Evaluate short- and long term efficacy of Cabozantinib treatment via PFS. | 24 months | Progression free survival (PFS). |
| Evaluate exposure time. | 12 months | Time on drug (TOD). |
| Assess quality-of-life during and after Cabozantinib treatment. | 15 months | EORTC QLQ-C30 Quality of Life Questionnaire monthly for 12 months after treatment start and after 15 months. Different questions regarding Quality of Life on a scale of 1 - 4. The lower the numbers, the better the quality of Life. |
| Evaluate short- and long term efficacy of Cabozantinib treatment via OS. | 24 months | Overall survival (OS). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety of Cabozantinib via AE and SAE assessment. | 24 months | Adverse events and serious adverse events will be assessed in contingency tables. |
Countries
Austria, Germany
Outcome results
None listed